Clinical use of lentiviral vectors.

Clinical use of lentiviral vectors.
复制标题

DOI:
10.1038/s41375-018-0106-0
复制
发表时间:
2018-07
期刊:
影响因子:
11.4
通讯作者:
O'Doherty U
O'Doherty U
中科院分区:
医学1区
文献类型:
--
作者:
Milone MC;O'Doherty U

文献摘要

参考文献

被引文献

相似文献

病毒载体为修饰真核细胞提供了一种有效的手段,它们的使用现在在学术实验室和工业界的研究和临床基因治疗应用中很常见。源自人类免疫缺陷病毒的慢病毒载体在过去二十年中得到了广泛的研究和优化。第三代自失活慢病毒载体最近已用于多项临床试验,将基因引入造血干细胞,以纠正原发性免疫缺陷和血红蛋白病。这些载体还被用来将基因引入成熟 T 细胞,通过传递嵌合抗原受体 (CAR) 或克隆 T 细胞受体产生癌症免疫力。使用慢病毒载体设计的 CAR T 细胞疗法在 B 细胞恶性肿瘤患者中取得了显着的临床成功,从而导致监管部门批准了第一个使用慢病毒载体的基因工程细胞疗法。在这篇综述中,我们讨论了临床医生感兴趣的慢病毒载体的几个方面,包括慢病毒载体开发的概述、病毒载体目前用于治疗原发性免疫缺陷和癌症的用途、慢病毒载体的大规模生产以及对接受基因治疗产品治疗的患者的长期随访。
Viral vectors provide an efficient means for modification of eukaryotic cells, and their use is now commonplace in academic laboratories and industry for both research and clinical gene therapy applications. Lentiviral vectors, derived from the human immunodeficiency virus, have been extensively investigated and optimized over the past two decades. Third-generation, self-inactivating lentiviral vectors have recently been used in multiple clinical trials to introduce genes into hematopoietic stem cells to correct primary immunodeficiencies and hemoglobinopathies. These vectors have also been used to introduce genes into mature T cells to generate immunity to cancer through the delivery of chimeric antigen receptors (CARs) or cloned T-cell receptors. CAR T-cell therapies engineered using lentiviral vectors have demonstrated noteworthy clinical success in patients with B-cell malignancies leading to regulatory approval of the first genetically engineered cellular therapy using lentiviral vectors. In this review, we discuss several aspects of lentiviral vectors that will be of interest to clinicians, including an overview of lentiviral vector development, the current uses of viral vectors as therapy for primary immunodeficiencies and cancers, large-scale manufacturing of lentiviral vectors, and long-term follow-up of patients treated with gene therapy products.
DOI: 10.1007/s00005-010-0063-4
发表时间: 2010-04
影响因子: 3.2
作者:
Escors, David;Breckpot, Karine
通讯作者: Breckpot, Karine
DOI: 10.1038/nrmicro3503
发表时间: 2015-08
期刊: Nature reviews. Microbiology
影响因子: --
作者:
Campbell EM;Hope TJ
通讯作者: Hope TJ
DOI: 10.1126/scitranslmed.aaa1405
发表时间: 2015-03-04
影响因子: 17.1
作者:
Cantore, Alessio;Ranzani, Marco;Naldini, Luigi
通讯作者: Naldini, Luigi
DOI: 10.1038/nature09328
发表时间: 2010-09-16
期刊: Nature
影响因子: 64.8
作者:
通讯作者: --
DOI: 10.1002/bies.201500051
发表时间: 2015-11
期刊: BIOESSAYS
影响因子: 4
作者:
Demeulemeester, Jonas;De Rijck, Jan;Gijsbers, Rik;Debyser, Zeger
通讯作者: Debyser, Zeger